ROAR GILL LIMITED

Company number 08310481 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment: ROAR GILL LIMITED

1. Financial Health Score: D+

Explanation: While the patient is still breathing (solvent) and has a history of remarkable recovery, the most recent fiscal year (2024) reveals acute symptoms of financial distress. The sudden evaporation of working capital and a massive spike in short-term liabilities indicate a severe liquidity crisis that requires immediate intervention.

2. Key Vital Signs

  • Blood Pressure (Liquidity Ratio): 0.99:1 (Current Assets £111,452 / Current Liabilities £112,315). A ratio below 1:1 means the company has less than £1 in short-term assets for every £1 of short-term debt due. This is a dangerous drop from a very healthy 3.85:1 in 2023, indicating high blood pressure and a potential cash flow crunch.
  • Heart Rate (Equity Pulse): £15,537 (Shareholders' Funds). The company's net worth has flatlined compared to the previous year (£95,395), representing an £79,858 hemorrhage in equity.
  • Cholesterol Levels (Liabilities): £112,315 (Creditors due within one year). Short-term obligations have skyrocketed by over 250% from £31,921 in 2023. This dangerous blockage threatens the company's day-to-day operations.
  • Organ Growth (Fixed Assets): £16,400. Up from £4,343 in the prior year. While growth can be positive, this expansion appears to have been funded by unhealthy short-term debt rather than organic cash flow.

3. Diagnosis

Severe Acute Liquidity Shock following a Period of Remission

Looking at the patient's medical history, ROAR GILL LIMITED (formerly THE PIZZA LAUNDRY LTD) was in critical condition between 2016 and 2018, suffering from negative net assets (insolvency). However, following what appears to be a pivot to coffee production, the business staged an impressive recovery, building up a healthy equity position of over £127k by 2021.

Unfortunately, the 2024 accounts show a severe relapse. The primary symptom is the sudden, massive accumulation of short-term creditors (£112k), which has entirely wiped out the company's working capital. Net current assets have shifted from a healthy £91,052 to a negative £863.

This presentation typically suggests one of two underlying conditions: 1. Severe Trading Losses: The business may have incurred significant operating losses in 2024, eating through cash reserves and forcing it to delay paying trade creditors. 2. Dangerous Debt-Funded Expansion: The company may have taken on substantial short-term debt or deferred supplier payments to fund the purchase of new fixed assets (which grew by £12k). Using short-term liabilities to fund long-term assets is a classic mismatch that starves the business of working capital.

Because the company files as a micro-entity, the Profit & Loss account is hidden, meaning we cannot see the exact tumor (trading loss) or injury causing the bleed, but the symptoms in the balance sheet are undeniable.

4. Recommendations

  • Emergency Triage (Cash Flow Management): With current liabilities exceeding current assets, the company must prioritize cash collection and delay non-essential cash outflows. Daily cash flow forecasting is essential to avoid defaulting on obligations.
  • Debt Restructuring (Surgery): The £112k in short-term creditors is unsustainable. The directors should negotiate extended payment terms with suppliers or seek a long-term loan to refinance the short-term debt. Moving short-term debt to long-term debt will give the business the breathing room it needs to recover.
  • Review Asset Strategy: If the increase in fixed assets was funded by short-term creditor pressure, the company must ensure these assets are generating an immediate return. If not, consider whether asset disposals are necessary to raise emergency cash.
  • Monitor the Parent (Futuretronix Limited): As the majority shareholder (owning over 75%), Futuretronix Limited may need to provide financial support. A capital injection or a formal director's loan may be required to stabilize the patient if trading cannot clear the liabilities quickly.

Perspective: Financial Health Diagnostician · Model: glm-5.1 · Generated 14 August 2026